Table 2.
Prevalence of CCSVI in multiple sclerosis patients vs. controls – selected studies.
| Authors | MS patients | Non-MS patients | Positive CCSVI criteria in MS patients [%] | Positive CCSVI criteria in non-MS patients[%] |
|---|---|---|---|---|
| Zamboni P. et al. [32] | 65 | 235 | 100% | 0% |
| Al-Omari M.H. et al. [33] | 25 | 25 | 84% | 0% |
| Doepp F. et al. [13] | 56 | 20 | 0% | 0% |
| Baracchini C. et al. [17] | 50 | 50 | 16% | 2% |
| Mayer C.A. et al. [18] | 20 | 20 | 0% | 5% |
| Zivadinov R. et al.[11] | 289 | 163 | 56.1% | 22.7% |
| Floris R. et al. [34] | 40 | 34 | 55% | 35% |
| Patti F. et al. [35] | 148 | 172 | 18.9% | 6.4% |
| Lanzillo R. et al. [36] | 146 | 38 | 76% | 16% |
| Leone M.A. et al. [37] | 68 | 68 | 30.9% | 33.8% |
| Van den Berg P.J. et al. [38] | 90 | 41 | 9% | 0% |
| Chambers B. et al. [39] | 70 | 70 | 0% | 1.4% |
| Barreto A.D. et al. [19] | 200 | 76 | 3.88% | 7.14% |
| Imperiale D. et al. [40] | 80 | 41 | 17.5% | 7.3% |
| Rodger I.W. et al. [41] | 99 | 100 | 1% | 0% |
| Brod S.A. et al. [42] | 206 | 70 | 3.88% | 7.14% |
| Comi G. et al. [43] | 1165 | 376 | 3.26% | 2.13% |
| Traboulsee A.L. et al. [44] | 79 | 43 | 44% | 45% |
| Tromba L. et al. [45] | 112 | 67 | 59.8% | 0% |